Evidence map›Paper›PMID 37096593›Full record

ArticleBriefings in bioinformatics2023

BindingSite-AugmentedDTA: enabling a next-generation pipeline for interpretable prediction models in drug repurposing.

Niloofar Yousefi, Mehdi Yazdani-Jahromi, Aida Tayebi, Elayaraja Kolanthai, Craig J Neal, Tanumoy Banerjee, Agnivo Gosai, Ganesh Balasubramanian, Sudipta Seal, Ozlem Ozmen Garibay

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Acoustofluidic Engineering of Functional Vessel-on-a-Chip.ACS biomaterials science & engineering · 2023
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Niloofar YousefiIndustrial Engineering and Management Systems, University of Central Florida, 32816, 4000 Central Florida Blvd., Orlando, FL, USA.
Mehdi Yazdani-JahromiComputer Science, University of Central Florida, 32816, 4000 Central Florida Blvd., Orlando, FL, USA.
Aida TayebiIndustrial Engineering and Management Systems, University of Central Florida, 32816, 4000 Central Florida Blvd., Orlando, FL, USA.
Elayaraja KolanthaiCollege of Medicine, Bionix Cluster, University of Central Florida, 4000 Central Florida Blvd., Orlando 32816, FL, USA.
Craig J NealCollege of Medicine, Bionix Cluster, University of Central Florida, 4000 Central Florida Blvd., Orlando 32816, FL, USA.
Tanumoy BanerjeeDepartment of Mechanical Engineering and Mechanics, Lehigh University, Bethlehem 18015, PA, USA.
Agnivo GosaiIndependent Researcher, Corning, NY, USA.
Ganesh BalasubramanianDepartment of Mechanical Engineering and Mechanics, Lehigh University, Bethlehem 18015, PA, USA.
Sudipta SealCollege of Medicine, Bionix Cluster, University of Central Florida, 4000 Central Florida Blvd., Orlando 32816, FL, USA.
Ozlem Ozmen GaribayIndustrial Engineering and Management Systems, University of Central Florida, 32816, 4000 Central Florida Blvd., Orlando, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While research into drug-target interaction (DTI) prediction is fairly mature, generalizability and interpretability are not always addressed in the existing works in this field. In this paper, we propose a deep learning (DL)-based framework, called BindingSite-AugmentedDTA, which improves drug-target affinity (DTA) predictions by reducing the search space of potential-binding sites of the protein, thus making the binding affinity prediction more efficient and accurate. Our BindingSite-AugmentedDTA is highly generalizable as it can be integrated with any DL-based regression model, while it significantly improves their prediction performance. Also, unlike many existing models, our model is highly interpretable due to its architecture and self-attention mechanism, which can provide a deeper understanding of its underlying prediction mechanism by mapping attention weights back to protein-binding sites. The computational results confirm that our framework can enhance the prediction performance of seven state-of-the-art DTA prediction algorithms in terms of four widely used evaluation metrics, including concordance index, mean squared error, modified squared correlation coefficient ($r^2_m$) and the area under the precision curve. We also contribute to three benchmark drug-traget interaction datasets by including additional information on 3D structure of all proteins contained in those datasets, which include the two most commonly used datasets, namely Kiba and Davis, as well as the data from IDG-DREAM drug-kinase binding prediction challenge. Furthermore, we experimentally validate the practical potential of our proposed framework through in-lab experiments. The relatively high agreement between computationally predicted and experimentally observed binding interactions supports the potential of our framework as the next-generation pipeline for prediction models in drug repurposing.

Indexed as

AlgorithmsDrug RepositioningBinding SitesDrug DevelopmentProteinsProteinsbinding sitesdeep learningdrug–target affinitydrug–target interactionDTA databaseDTA softwaremachine learningSARS-CoV-2

Identifiers

PMID37096593
PMCPMC10199763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.